Evidence map›Paper›PMID 42290307›Full record

ArticleBiotechnology progress

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins.

Peter J Halfmann, Augustine Duffy, Alex Wee, Noah Anderson, Jackson Terrell, Yoshihiro Kawaoka, Ravi S Kane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peter J HalfmannDepartment of Pathobiological Sciences, School of Veterinary Medicine, Influenza Research Institute, University of Wisconsin, Madison, Wisconsin, USA.
Augustine DuffySchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Alex WeeSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Noah AndersonWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Jackson TerrellSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Yoshihiro KawaokaDepartment of Pathobiological Sciences, School of Veterinary Medicine, Influenza Research Institute, University of Wisconsin, Madison, Wisconsin, USA.
Ravi S KaneSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-3084-4098

Funding

PanCorVac (Center for Pan-Coronavirus Vaccine Development)P01AI165077 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KAWAOKA, YOSHIHIRO · 2021 to 2023
$11.6M
T32 Research Training Program in ImmunoEngineeringT32EB021962 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI JULIA E BABENSEE · 2017 to 2026
$1.9M
Garry Betty/V Foundation Chair FundJapan Program for Infectious Diseases Research and Infrastructure JP23wm0125002NIAID NIH HHS P01 AI165077NIBIB NIH HHS T32 EB021962NIH HHS P01AI165077NIH HHS T32 EB021962University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) JP233fa627001
6 · The paper itself

Abstract

Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in immunocompromised and elderly individuals. Frequent adaptive evolution in the spike proteins of these embecoviruses and the potential for zoonotic transmission from a large animal reservoir necessitates the characterization of the immunogenic landscape of the spike proteins of embecoviruses. Here, we constructed nanoparticle vaccines displaying the spike antigens from OC43, HKU1 A, or HKU1 B, as well as a bivalent formulation incorporating spike antigens from OC43 and HKU1 A. Immunization of mice elicited spike-specific IgG antibody responses, with endpoint titers demonstrating cross-reactivity among clade-matched viruses. Notably, the bivalent formulation elicited antibody responses comparable to those of monovalent vaccines against matched antigens. These findings inform future design of vaccines against human-infecting embecoviruses and could serve as an important step toward a universal vaccine against common cold causing coronaviruses.

Indexed as

CoronavirusNanoparticlesSpike Glycoprotein, CoronavirusViral VaccinesAnimalsAntibodies, ViralFemaleHumansImmunoglobulin GMiceMice, Inbred BALB CNanovaccinesAntibodies, ViralImmunoglobulin GNanovaccinesSpike Glycoprotein, CoronavirusViral Vaccinescommon coldcoronavirusembecovirusnanoparticlespike proteinvaccine

Identifiers

PMID42290307
PMCPMC13636613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.